OmniAb (OABI) Return on Capital Employed (2021 - 2026)
OmniAb (OABI) reported Return on Capital Employed of 20.43% for Q1 2026, up 282.0% year-over-year from 5.35% in Q1 2025, and up 14.39% on a QoQ basis from 23.86% in Q4 2025.
OmniAb (OABI) has 6 years of Return on Capital Employed data on file, last reported at 20.43% in Q1 2026.
- Quarterly Return on Capital Employed rose 282.0% year-over-year to 20.43% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20.43% (up 282.0% YoY) and the FY2025 annual result came in at 23.22%, down 100.0% from the prior year.
- Return on Capital Employed grew to 20.43% in Q1 2026 per OABI's latest filing, from 23.86% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 6.8% in Q1 2023 and bottomed at 31.34% in Q3 2022.
- The 5-year median for Return on Capital Employed is 23.77% (2024), against an average of 19.97%.
- The widest annual swing landed in 2023, when Return on Capital Employed surged 2085 bps; it then slumped 1732 bps in 2024.
- Tracing OABI's Return on Capital Employed over 5 years: stood at 8.78% in 2022, then plunged by 119 bps to 19.26% in 2023, then declined by 23 bps to 23.77% in 2024, then retreated by 0 bps to 23.86% in 2025, then rose by 14 bps to 20.43% in 2026.
- Per Business Quant, the three latest OABI Return on Capital Employed figures stand at 20.43% (Q1 2026), 23.86% (Q4 2025), and 23.87% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | -20.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.43% |
| Dec 31, 2025 | -23.86% |
| Sep 30, 2025 | -23.87% |
| Jun 30, 2025 | -24.53% |
| Mar 31, 2025 | -23.25% |
| Dec 31, 2024 | -23.77% |
| Sep 30, 2024 | -24.95% |
| Jun 30, 2024 | -24.30% |
| Mar 31, 2024 | -24.11% |
| Dec 31, 2023 | -19.26% |
| Sep 30, 2023 | -10.49% |
| Jun 30, 2023 | -8.77% |
| Mar 31, 2023 | -6.80% |
| Dec 31, 2022 | -8.78% |
| Sep 30, 2022 | -31.34% |
| Jun 30, 2022 | -24.53% |
| Mar 31, 2022 | -16.52% |
| Dec 31, 2021 | -14.23% |